Latest current cash for EFTRW: $630K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), EFTRW shows a current cash of $630K. That compares with $15K in the prior-year period — up 4186.5% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, EFTRW's current cash is now $630K (was $15K) — a 4186.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether eFFECTOR Therapeutics- Warrants (26/08/2026) is outperforming or lagging.
Tracking EFTRW's current cash over time shows whether eFFECTOR Therapeutics- Warrants (26/08/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $630K That compares with $15K in the prior-year period — up 4186.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this current cash page, Stockcircle has eFFECTOR Therapeutics- Warrants (26/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $630K) with ownership activity and broader fundamentals.
eFFECTOR Therapeutics- Warrants (26/08/2026)'s current cash is $630K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.